GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crism Therapeutics Corp (LSE:CRTX) » Definitions » Capex-to-Operating-Income

Crism Therapeutics (LSE:CRTX) Capex-to-Operating-Income : 0.00 (As of Jun. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Crism Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Crism Therapeutics's Capital Expenditure for the six months ended in Jun. 2024 was £-0.01 Mil. Its Operating Income for the six months ended in Jun. 2024 was £-0.30 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Crism Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for Crism Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crism Therapeutics Capex-to-Operating-Income Chart

Crism Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Crism Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Crism Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, Crism Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crism Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Crism Therapeutics's Capex-to-Operating-Income falls into.


;
;

Crism Therapeutics Capex-to-Operating-Income Calculation

Crism Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -1.773
=N/A

Crism Therapeutics's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.007) / -0.3
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Crism Therapeutics  (LSE:CRTX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Crism Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Crism Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Crism Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.

Crism Therapeutics Headlines

No Headlines